Proteogenomic discovery engine for exposing the exposed: splice surface therapeutic targets

Active Grant Awarded

Award ID
R41TR006343
Recipient
Awarding agency
Obligated
$321,316

Award facts

Completion date 34% complete
Place of performance
New York, NY 10012, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded Neosplice Therapeutics, Inc. $321,316 on July 20, 2026, under grant R41TR006343, a Phase I STTR award. It is assigned to CFDA 93.350, National Center for Advancing Translational Sciences, runs through July 19, 2027, and performs work in New York, NY 10012.

The award translates academic advances into the NeoSplice Discovery Engine, a modular, disease-agnostic platform that resolves full-length isoforms in heterogeneous samples, scores candidates for surface exposure, safety, and tractability, and confirms stable surface expression with targeted protein assays. The work targets splice surface antigens (SSAs), a class of extracellular epitopes arising from alternative splicing. Aim 1 generates a ranked catalog of SSA candidates in a defined disease model, packaged as concise, partner-ready target dossiers. Aim 2 establishes a targeted validation workflow to verify isoform-specific surface expression across prioritized candidates and scale to larger panels.

Phase I deliverables include a versioned scoring framework, prioritized SSA lists with per-target summaries, and validated assay panels suitable for therapeutic programs. The recipient states that this work positions it for Phase II lead generation, partnerships, and co-development of isoform-resolved therapies across multiple indications.

Description

Abstract
A central barrier to next-generation immunotherapies is the scarcity of disease-specific extracellular targets. A major untapped source of targets arises from alternative splicing, which generates thousands of aberrant isoforms across many complex diseases. Many of these isoforms alter extracellular domains of transmembrane proteins, producing "splice surface antigens" (SSAS)-a novel class of epitopes with immense therapeutic potential. Despite strong biology rationale, no scalable, end-to-end platform exists to systematically discover, prioritize, and validate SSAS for drug development. This sttr phase I will translate recent academic advances into the neosplice discovery engine™, a modular, disease-agnostic platform that 1) resolves full-length isoforms in heterogeneous samples, 2) scores candidates for surface exposure, safety, and tractability, and 3) confirms stable surface expression with targeted protein assays. Aim 1 will generate a ranked catalog of SSA candidates in a defined disease model, producing concise, partner-ready target dossiers. Aim 2 will establish a targeted validation workflow to verify isoform-specific surface expression across prioritized candidates and scale to larger panels. Phase I deliverables include a versioned scoring framework, prioritized SSA lists with per-target summaries, and validated assay panels suitable for therapeutic programs. This project lays the foundation to expand the actionable target space beyond canonical proteins. IT will position US for phase II lead generation, partnerships, and CO-development of safer, more precise isoform-resolved therapies across multiple indications.

Quick answers

Who received award R41TR006343?

R41TR006343 was awarded to Neosplice Therapeutics, Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on July 20, 2026.

How much is award R41TR006343 worth?

$321,316 has been obligated on R41TR006343.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award